These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8689102)

  • 1. Phase II trials in Ta, T1 bladder cancer. The marker tumour concept.
    van der Meijden AP; Hall RR; Kurth KH; Bouffioux C; Sylvester R
    Br J Urol; 1996 May; 77(5):634-7. PubMed ID: 8689102
    [No Abstract]   [Full Text] [Related]  

  • 2. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
    Hall MC; Chang SS; Dalbagni G; Pruthi RS; Seigne JD; Skinner EC; Wolf JS; Schellhammer PF
    J Urol; 2007 Dec; 178(6):2314-30. PubMed ID: 17993339
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumour location adjacent to the ureteric orifice in primary Ta/T1 bladder cancer is predictive of recurrence.
    Jancke G; Rosell J; Jahnson S
    Scand J Urol; 2016; 50(1):33-8. PubMed ID: 26202687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.
    Shang PF; Kwong J; Wang ZP; Tian J; Jiang L; Yang K; Yue ZJ; Tian JQ
    Cochrane Database Syst Rev; 2011 May; (5):CD006885. PubMed ID: 21563157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials.
    Van Der Meijden A; Sylvester R; Collette L; Bono A; Ten Kate F
    J Urol; 2000 Nov; 164(5):1533-7. PubMed ID: 11025698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.
    Packiam VT; Lamm DL; Barocas DA; Trainer A; Fand B; Davis RL; Clark W; Kroeger M; Dumbadze I; Chamie K; Kader AK; Curran D; Gutheil J; Kuan A; Yeung AW; Steinberg GD
    Urol Oncol; 2018 Oct; 36(10):440-447. PubMed ID: 28755959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001.
    Gårdmark T; Bladström A; Hellsten S; Malmström PU;
    Scand J Urol Nephrol; 2006; 40(4):276-82. PubMed ID: 16916767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 AND TIS).
    Lamm DL
    J Urol; 2000 Jun; 163(6):1890-1. PubMed ID: 10799217
    [No Abstract]   [Full Text] [Related]  

  • 9. A standardization method to adjust for the effect of patient selection in phase II clinical trials.
    Mazumdar M; Fazzari M; Panageas KS
    Stat Med; 2001 Mar; 20(6):883-92. PubMed ID: 11252010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.
    Klaassen Z; Kamat AM; Kassouf W; Gontero P; Villavicencio H; Bellmunt J; van Rhijn BWG; Hartmann A; Catto JWF; Kulkarni GS
    Eur Urol; 2018 Nov; 74(5):597-608. PubMed ID: 30017405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.
    Vashistha V; Quinn DI; Dorff TB; Daneshmand S
    BMC Cancer; 2014 Dec; 14():966. PubMed ID: 25515347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Herr HW
    Eur Urol; 2009 Apr; 55(4):920-1. PubMed ID: 18722043
    [No Abstract]   [Full Text] [Related]  

  • 13. The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practice.
    Reading J; Hall RR; Parmar MK
    Br J Urol; 1995 May; 75(5):604-7. PubMed ID: 7613798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical study of PMCJ-9 (Bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder.
    Akaza H; Koiso K; Ozono S; Kuroda M; Kameyama S; Okajima E; Kotake T; Kakizoe T; Kawabe K;
    Jpn J Clin Oncol; 2003 Aug; 33(8):382-90. PubMed ID: 14523057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Witjes JA
    Eur Urol; 2009 Apr; 55(4):919. PubMed ID: 18722044
    [No Abstract]   [Full Text] [Related]  

  • 16. IDM confirms significant results in bladder cancer program.
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):507. PubMed ID: 12113077
    [No Abstract]   [Full Text] [Related]  

  • 17. Bladder cancer clinical trials.
    Lerner SP
    Urol Oncol; 2005; 23(4):275-9. PubMed ID: 16018944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA flow cytometry and 67Ki proliferating index as prognostic factors of early recurrence and progression in G1-G2/Ta-T1 and G3/Ta-T1 transitional cell carcinoma of the bladder.
    Tizzani A; Casetta G; Gontero P; Giammò A; Ghabin H; Demurtas S; Pacchioni D
    Minerva Urol Nefrol; 1997 Sep; 49(3):141-3. PubMed ID: 9396221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical chemotherapy for superficial bladder tumors category Ta/T1: who should be treated and how?
    Kurth KH
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):30-5. PubMed ID: 8727808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
    Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
    Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.